Member Info for ogm4

It shows what's going on behind the scenes in terms of large trades

330,000 shares @ 9.52p

£31.42k

$9.2 billion

What an incredible offer!...

£23k, £24k, £26k trades arrived from yesterday

And here's another recent deal:

Boehringer Ingelheim's deal frenzy continues with $570M autoimmune pact

By Darren Incorvaia

Nov 4, 2025 8:00am

https://www.fiercebiotech.com/biotech/boehringer-ingelheims-deal-frenzy-continues-570m-autoimmune-pact

Celltrion looks beyond biosimilars with $744M pact for 2 preclinical autoimmune drugs

By James Waldron

Nov 4, 2025 6:15am

https://www.fiercebiotech.com/biotech/celltrion-looks-beyond-biosimilars-740m-pact-2-preclinical-autoimmune-drugs

Morning all,

Will we see a continuation of yesterday's rise?

Lanstead continuous selling should be finished by now as they must have completed their scheme after all the recent RNS's stating further reduced holdings, now even below 3%.

Lanstead must be running on fumes!...

They should be pretty much done selling by now

Sudden jump now...

Lanstead scrambling for shares now instead?

Some bigger trades being worked this morning...

11.20p

+12%

Here we go, take off!....

Lanstead could be running on fumes...

Probably hardly have any shares left by now...

Hundred million type of deals analogue made

Humira sort of scale, i.e elephant in the room

One or more commercial deals before year end

Another positive surprise expected from 'the left'

CSO having 'eureka' moment during ground breaking discovery

Tim as happy as 11 on scale of 10

Lot's of news flow and interviews expected before year end

...

Lanstead have been selling for months and months and months as per their portfolio strategy. Today's RNS is just another progress update of what they have been doing all year. Nothing shocking really in that sense, only further reducing their holding as per scheme.

Today's RNS has absolutely got nothing to do with the timing of the bio conference this week.

Lanstead will not be aware of any imminent deals as strict Non Disclosure Agreements will be in place, signed behind closed doors as per tender protocol.

Https://x.com/Share_Talk/status/1985242504304705967

GM all,

Immupharma seems rather well represented with the CEO, CSO and COO attending the Bio-Europe Conference in Vienna today and over the next two days.

Let's see if there will be any news this week.

Big market out there, hopefully IMM can make a difference for millions of people

The 14 Most Common Autoimmune Diseases—and Who’s Most at Risk for Each

By Dr. Patricia Varacallo, DO

Published on Oct. 31, 2025

https://www.thehealthy.com/autoimmune/the-14-most-common-autoimmune-diseases-and-whos-most-at-risk-for-each/

Bear in mind as Tim mentioned in one of the interviews earlier that they have completely overhauled the product being the new breakthrough innovation and you cannot compare it anymore with a few years ago. So any comparison with then is not much of use.

One of the things he promised earlier this year was the patent filing milestone to happen somewhere in the 2nd half of the year, which he already delivered successfully.

Patent filing done.

Box ticked.